Rev-erbα heterozygosity produces a dose-dependent phenotypic advantage in mice.

by Ryan D Welch, Cyrielle Billon, Amina Kameric, Thomas P Burris, Colin A Flaveny
Published 2020-01-01

The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis

by Kristine Griffett, Ryan D. Welch, Colin A. Flaveny, Grant R. Kolar, Brent A. Neuschwander-Tetri, Thomas P. Burris
Published 2015-04-01

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH

by Ryan D. Welch, Cyrielle Billon, McKenna Losby, Gonzalo Bedia-Diaz, Yuanying Fang, Amer Avdagic, Bahaa Elgendy, Thomas P. Burris, Kristine Griffett
Published 2022-03-01

Rev-Erb co-regulates muscle regeneration via tethered interaction with the NF-Y cistrome

by Ryan D. Welch, Chun Guo, Monideepa Sengupta, Katherine J. Carpenter, Natalie A. Stephens, Stacy A. Arnett, Marvin J. Meyers, Lauren M. Sparks, Steven R. Smith, Jinsong Zhang, Thomas P. Burris, Colin A. Flaveny
Published 2017-07-01

Intestinal α1-2-Fucosylation Contributes to Obesity and Steatohepatitis in MiceSummary

by Rongrong Zhou, Cristina Llorente, Jinling Cao, Livia S. Zaramela, Suling Zeng, Bei Gao, Shang-Zhen Li, Ryan D. Welch, Feng-Qing Huang, Lian-Wen Qi, Chuyue Pan, Yan Huang, Pengchen Zhou, Iris Beussen, Ying Zhang, Gregory Bryam, Oliver Fiehn, Lirui Wang, E-Hu Liu, Ruth T. Yu, Michael Downes, Ronald M. Evans, Karrie Goglin, Derrick E. Fouts, David A. Brenner, Lars Bode, Xuegong Fan, Karsten Zengler, Bernd Schnabl
Published 2021-01-01